<?php ?>
<!doctype html>
<html>
<head><style>@media only screen and (max-width: 620px){table.body h1{font-size:28px !important;margin-bottom:10px !important}table.body p,table.body ul,table.body ol,table.body td,table.body span,table.body a{}table.body .wrapper,table.body .preheader,table.body .header,table.body .prefooter,table.body .footer{padding:10px !important}table.body .content{padding:0 !important}table.body .container{padding:0 !important;width:100% !important}table.body .main{border-left-width:0 !important;border-radius:0 !important;border-right-width:0 !important}table.body .btn table{width:100% !important}table.body .btn a{width:100% !important}}</style>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <title>Evrenzo</title>
    
</head>
<body style="background-color:transparent;font-family:Arial,sans-serif;font-size:14px;line-height:1.4;margin:0;padding:0">

<table role="presentation" border="0" cellpadding="0" cellspacing="0" class="body" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%;background-color:#f6f6f6">
    <tr>
        <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">&#xA0;</td>
        <td class="container" style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top;display:block;margin:0 auto;max-width:580px;padding:10px;width:580px">
            <div class="content" style="box-sizing:border-box;display:block;margin:0 auto;max-width:600px;padding:10px">
                
                <div class="preheader" style="background-color: white;color: white;padding: 20px 40px">
                    <table role="presentation" border="0" cellpadding="0" cellspacing="0" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%">
                        <img src="https://fv-emails.s3.eu-west-1.amazonaws.com/evrenzo/logo.png" style="float:left;border:none;max-width:100%">

                    </table>
                </div>
                

                
                <table role="presentation" class="main" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%;background:#ffffff;border-radius:3px">

                    
                    <tr>
                        <td class="header" style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top;background-image:url(&quot;https://fv-emails.s3.eu-west-1.amazonaws.com/evrenzo/header_background.png&quot;);background-size:cover;padding:20px 40px">
                            <table role="presentation" border="0" cellpadding="0" cellspacing="0" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%">

                                <tr>
                                    <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                        <p style="font-size:22px;line-height:25px;color:#4D4D4F;margin-bottom:0;margin-top:20px;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            EVRENZO<sup>&#x25BC;TM</sup> has the potential to<br>
                                            change the clinical management of<br>
                                            symptomatic anaemia of CKD in<br>
                                            adult patients<sup>1</sup>
                                        </p>

                                        <p style="margin-bottom:170px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">

                                        </p>
                                        <p style="font-size:10px;line-height:13px;color:#fff;margin-bottom:0;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            <b>NOW WITH MARKETING AUTHORISATION IN THE EU AND UK</b>, indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)<sup>2</sup>
                                        </p>
                                    </td>
                                </tr>
                            </table>

                        </td>
                    </tr>

                    
                </table>
                

                
                <table role="presentation" class="main" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%;background:#ffffff;border-radius:3px">

                    
                    <tr>
                        <td class="wrapper" style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top;box-sizing:border-box;padding:20px 40px">
                            <table role="presentation" border="0" cellpadding="0" cellspacing="0" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%">
                                <tr>
                                    <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                        <br>
                                        <br>
                                    </td>
                                </tr>
                                <tr>
                                    <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            Dear [Title Name],
                                        </p>
                                        <p style="font-weight:bold;font-size:14px;line-height:22px;color:#007A33;margin-bottom:20px;font-family:Arial, sans-serif;margin:0 0 25px 0">
                                            For adult patients with symptomatic anaemia of CKD, EVRENZO is like a breath of fresh air, at high altitude
                                        </p>
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            Anaemia is a common complication of chronic kidney disease3 which can leave patients feeling tired, weak and breathless.<sup>4</sup>
                                        </p>
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            But the discovery of the HIF (hypoxia-inducible factor) pathway, which stimulates erythropoiesis when oxygen levels fall, has opened up a new approach to treating anaemia of CKD.<sup>1,5</sup>
                                        </p>
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            EVRENZO (roxadustat) is a first-in-class HIF-PH inhibitor5 which mimics the body&#x2019;s natural response to hypoxia.<sup>1</sup>
                                        </p>
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            By stimulating a coordinated erythropoietic response,1,2 EVRENZO helps
                                            adult patients with symptomatic anaemia of CKD to reach and maintain their target Hb levels.<sup>2</sup>
                                        </p>

                                        <p style="line-height:14px;color:#75787B;margin-bottom:0;font-weight:900;text-align:center;font-family:Arial, sans-serif;font-size:14px;margin:0 0 25px 0">
                                            Mean levels of haemoglobin (Per Protocol Set)<br>
                                            in the DOLOMITES clinical trial<sup>6</sup>
                                        </p>
                                        <p style="line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;font-weight:normal;margin:0 0 25px 0">
                                            <img src="https://fv-emails.s3.eu-west-1.amazonaws.com/evrenzo/graph.png" style="border:none;max-width:100%">

                                        </p>

                                        <p style="font-size:10px;line-height:15px;color:#75787B;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            The Phase III DOLOMITES study evaluated the efficacy and safety of EVRENZO compared to darbepoetin-alfa for the treatment of anaemia in patients with NND stage 3-5 CKD. **Target range was 10.0-12.0 g/dL.<sup>6</sup>
                                        </p>

                                        <p style="font-size:14px;line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            The primary endpoint analysis demonstrated non-inferiority of EVRENZO to darbepoetin-alfa in the proportion of patients achieving Hb response during the first 24 weeks. 89.5% of EVRENZO-treated patients achieved a Hb response vs. 78.0% of patients receiving darbepoetin-alfa during the first 24 weeks of treatment.<sup>6</sup>


                                        </p>
                                        <p style="font-size:14px;line-height:22px;color:#75787B;margin-bottom:20px;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            During clinical development, the general safety profile of EVRENZO was overall comparable to ESAs for the majority of safety variables evaluated and is reflective of the studied CKD populations.<sup>6,7-9</sup> Please see EVRENZO SmPC for the full
                                            safety profile.
                                        </p>
                                        <p style="font-size:14px;line-height:22px;color:#75787B;margin-bottom:0;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            <b style="color: #007A33">EVRENZO provides:</b><br>
                                            &#x2022;	Proven Hb efficacy,<sup>6</sup> with a reduced use of IV iron compared with ESA<sup>6</sup><br>
                                            &#x2022;	No increase in risk of cardiovascular events compared with ESA in patients in
                                            NDD-CKD and IDD-CKD<sup>&#x2020;*1</sup><br>
                                            &#x2022;	The convenience of an oral tablet taken three times per week on
                                            non-consecutive days<sup>1</sup><br>
                                        </p>
                                        <br><br>
                                        <p style="font-size:12px;line-height:16px;color:#75787B;margin-bottom:0;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                            <b>Prescribing information and adverse event reporting information can be found by clicking the link in the grey bar below.</b>
                                        </p>

                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>

                    
                </table>
                


                
                <div class="prefooter" style="background-color: #fff;color: #75787B;padding: 0 40px 10px 40px;">
                    <table role="presentation" border="0" cellpadding="0" cellspacing="0" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%">
                        <tr>
                            <td style="background-color:gray;color:white;font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <a href="https://dhgd52pup2eiv.cloudfront.net/23ffe42b-4e89-48e1-b8d8-08b726ed94c1/7707651c-46f9-4279-8009-4546b4b54878/7707651c-46f9-4279-8009-4546b4b54878_source__v.pdf" target="_blank" style="color:#fff;text-decoration:none">
                                    <p style="font-size:11px;line-height:18px;margin:0;text-align:center;padding:15px;font-family:Arial, sans-serif;font-weight:normal">
                                        CLICK HERE FOR LOCAL PRESCRIBING INFORMATION
                                    </p>
                                </a>
                            </td>
                        </tr>
                        <tr>
                            <td style="background-color:white;padding:10px;color:white;margin-bottom:20px;font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <p style="font-size:10px;line-height:18px;margin:0;text-align:center;font-family:Arial, sans-serif;font-weight:normal">
                                </p>
                            </td>
                        </tr>

                        <tr>
                            <td style="border:1px solid gray;padding:25px;font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <p style="font-size:10px;line-height:18px;margin:0;font-family:Arial, sans-serif;font-weight:normal">
                                    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.
                                </p>
                            </td>
                        </tr>

                        <tr>
                            <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <p style="font-size:10px;line-height:18px;color:#75787B;margin-top:25px;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                    The hyperlinks on this page will take you to non-Astellas websites.
                                    Astellas does not endorse or accept liability for sites controlled by third parties.
                                    To arrange a call with an Astellas representative, please use the contact details below.
                                </p>
                                <p style="font-size:10px;line-height:18px;color:#75787B;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                    Sincerely,<br>
                                    Astellas<br>
                                    marketing.gb@astellas.com
                                </p>
                                <p style="font-size:10px;line-height:18px;color:#75787B;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                    *Please see EVRENZO SmPC for further information on CV and mortality risk.
                                </p>
                                <p style="font-size:10px;line-height:18px;color:#75787B;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                    &#x2020;Incident dialysis defined as &#x2265;2 weeks and &#x2264;4months
                                    CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; IV, intravenous; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.
                                </p>
                                <p style="font-size:10px;line-height:18px;color:#75787B;font-family:Arial, sans-serif;font-weight:normal;margin:0 0 25px 0">
                                    <b>References</b><br>
                                    1. Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.<br>
                                    2. EVRENZO SmPC.<br>
                                    3. Babitt JL, Lin HY. J Am Soc Nephrol. 2012;(10)23:1631-1634.<br>
                                    4. Mathias SD et al. J Patient-Reported Outcomes. 2020;4,64. https://doi.org/10.1186/s41687-020-00215-8<br>
                                    5. Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.<br>
                                    6. Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616-1628. https://doi.org/10.1093/ndt/gfab191<br>
                                    7. Fishbane S et al. Poster session presented at: American Society of Nephrology; 5-10 November 2019; Washington, DC, USA. (Poster no. FR-OR131).<br>
                                    8. Esposito C et al. Poster session presented: American Society of Nephrology; 5-10 November 2019; Washington, DC, USA (Poster no. SA-P0225).<br>
                                    9. Charytan C et al. Kidney Int Rep. 2021;6(7):1829-1839.<br>
                                    10. Supplement to: Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616-1628.

                                </p>
                                <p style="font-size:10px;line-height:18px;color:#75787B;margin:0;font-family:Arial, sans-serif;font-weight:normal">
                                    EVZ_2022_0016_UK | February 2022
                                </p>
                            </td>
                        </tr>

                    </table>
                </div>
                

                
                <div class="footer" style="background-color: #fff;color: white;padding: 0 40px 20px 40px">
                    <table role="presentation" border="0" cellpadding="0" cellspacing="0" style="border-collapse:separate;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%">
                        <tr>
                            <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <img src="https://fv-emails.s3.eu-west-1.amazonaws.com/evrenzo/footer-logo.png" style="float:left;border:none;max-width:100%">
                            </td>
                        </tr>
                        <tr>
                            <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">
                                <br>
                                <br>
                                <p style="font-size:10px;line-height:18px;color:#75787B;margin:0;font-family:Arial, sans-serif;font-weight:normal">
                                    Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
                                </p>
                            </td>
                        </tr>
                    </table>
                </div>
                

            </div>
        </td>
        <td style="font-family:Arial, sans-serif;font-size:14px;vertical-align:top">&#xA0;</td>
    </tr>
</table>
</body>
</html>